Emerald Advisers LLC Increases Stock Position in TransMedics Group, Inc. (NASDAQ:TMDX)

Emerald Advisers LLC raised its position in shares of TransMedics Group, Inc. (NASDAQ:TMDX - Free Report) by 22.4% during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 454,794 shares of the company's stock after purchasing an additional 83,083 shares during the period. TransMedics Group makes up approximately 1.4% of Emerald Advisers LLC's holdings, making the stock its 21st largest holding. Emerald Advisers LLC owned approximately 1.34% of TransMedics Group worth $30,599,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in TMDX. NBC Securities Inc. bought a new stake in TransMedics Group in the 1st quarter worth approximately $25,000. Atlas Capital Advisors Inc. purchased a new stake in TransMedics Group in the fourth quarter worth approximately $31,000. AlphaQuest LLC purchased a new stake in TransMedics Group in the fourth quarter worth approximately $52,000. Sava Infond d.o.o. purchased a new stake in TransMedics Group in the fourth quarter worth approximately $94,000. Finally, GAMMA Investing LLC boosted its stake in TransMedics Group by 551.7% in the first quarter. GAMMA Investing LLC now owns 1,564 shares of the company's stock worth $105,000 after buying an additional 1,324 shares in the last quarter. Hedge funds and other institutional investors own 99.67% of the company's stock.

Insider Buying and Selling

In related news, Director Edward M. Basile sold 6,000 shares of the business's stock in a transaction that occurred on Friday, May 9th. The shares were sold at an average price of $115.63, for a total value of $693,780.00. Following the completion of the transaction, the director directly owned 732 shares in the company, valued at $84,641.16. The trade was a 89.13% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Anil P. Ranganath sold 686 shares of the business's stock in a transaction that occurred on Monday, June 9th. The stock was sold at an average price of $139.80, for a total transaction of $95,902.80. Following the completion of the transaction, the insider owned 13,955 shares of the company's stock, valued at approximately $1,950,909. The trade was a 4.69% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 12,418 shares of company stock worth $1,512,613 in the last three months. Insiders own 7.00% of the company's stock.

Analyst Upgrades and Downgrades

TMDX has been the subject of several research reports. Oppenheimer upped their target price on TransMedics Group from $130.00 to $150.00 and gave the stock an "outperform" rating in a research note on Tuesday, June 17th. Needham & Company LLC reaffirmed a "hold" rating on shares of TransMedics Group in a research note on Tuesday, June 17th. Finally, Piper Sandler reaffirmed an "overweight" rating and set a $145.00 price objective (up from $125.00) on shares of TransMedics Group in a research note on Wednesday, June 4th. Three analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $127.33.

TransMedics Group Stock Down 9.9%

Shares of TMDX stock traded down $12.32 during trading hours on Friday, hitting $112.46. 2,553,123 shares of the company's stock traded hands, compared to its average volume of 1,378,790. The stock's fifty day simple moving average is $125.49 and its two-hundred day simple moving average is $90.65. TransMedics Group, Inc. has a 12-month low of $55.00 and a 12-month high of $177.37. The stock has a market cap of $3.80 billion, a price-to-earnings ratio of 82.69 and a beta of 2.06. The company has a quick ratio of 8.32, a current ratio of 9.10 and a debt-to-equity ratio of 1.92.

TransMedics Group (NASDAQ:TMDX - Get Free Report) last released its earnings results on Thursday, May 8th. The company reported $0.70 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.29 by $0.41. TransMedics Group had a net margin of 10.03% and a return on equity of 21.88%. The firm had revenue of $143.54 million during the quarter, compared to analyst estimates of $123.39 million. During the same period last year, the business earned $0.35 earnings per share. The business's revenue was up 48.2% on a year-over-year basis. On average, analysts expect that TransMedics Group, Inc. will post 1 EPS for the current year.

TransMedics Group Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.